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Inflammatory breast carcinoma (IBC) is one of the most lethal forms of
human breast cancer, and effective treatment for IBC is an unmet
clinical need in contemporary oncology. Tumor-targeted theranostic
approaches are emerging in precisionmedicine, but only a few specific
biomarkers are available. Here we report up-regulation of the 78-kDa
glucose-regulated protein (GRP78) in two independent discovery and
validation sets of specimens derived from IBC patients, suggesting
translational promise for clinical applications. We show that a GRP78-
binding motif displayed on either bacteriophage or adeno-associated
virus/phage (AAVP) particles or loop-grafted onto a human antibody
fragment specifically targets orthotopic IBC and other aggressive
breast cancer models in vivo. To evaluate the theranostic value, we
used GRP78-targeting AAVP particles to deliver the human Herpes
simplex virus thymidine kinase type-1 (HSVtk) transgene, obtaining
simultaneous in vivo diagnosis through PET imaging and tumor treat-
ment by selective activation of the prodrug ganciclovir at tumor sites.
Translation of this AAVP system is expected simultaneously to image,
monitor, and treat the IBC phenotype and possibly other aggressive
(e.g., invasive and/or metastatic) subtypes of breast cancer, based on
the inducible cell-surface expression of the stress-response chaperone
GRP78, and possibily other cell-surface receptors in human tumors.
inflammatory breast cancer | ligand-directed theranostics |
molecular imaging | gene therapy | AAVP
Breast cancer remains a major cause of cancer death in women(1), and one of its most lethal presentations is inflammatory
breast carcinoma (IBC), a clinicopathological diagnosis character-
ized by diffuse erythema/edema involving the skin of the breast (a
sign classically known as “peau d’orange”) caused by tumor emboli
within the dermal lymphatics. Although IBC comprises <5% of
breast cancer cases, the tumor accounts for more than 10% of
breast cancer mortality in the United States (2, 3). IBC is consid-
ered aggressive because it evolves rapidly—over days to weeks
rather than months—with most patients presenting with lymph
node involvement and more than 30% of patients having distant
metastases at diagnosis (4, 5). Although IBC, like non-IBC breast
cancers, is a heterogeneous disease and can occur as any of the
five molecular subtypes, the IBC is most commonly ErbB2 over-
expressing or triple negative (6), thus rendering a large armamen-
tarium of targeted drugs ineffective. Finally, IBC generally presents
with high-grade histology, elevated cell proliferation rate, and
angiolymphatic invasion (5, 7). Indeed, the hallmark lymphatic in-
vasion dictates the requirement for initial systemic treatment of IBC,
because micrometastatic disease likely has occurred even in the
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absence of overt metastasis, as evidenced by the high incidence of
tumor recurrence. Aggressive local management with surgery and
nodal radiotherapy typically follows systemic combination chemo-
therapy (4–7). Collectively, the pathological and molecular under-
pinnings of the disease contribute to the poor prognosis of IBC
patients relative to other, more common subtypes of human breast
cancer (8). Therefore IBC is unequivocally considered a formidable
clinical challenge in contemporary cancer medicine (2–8). Within
this clinical context, the emerging field of “theranostic” (a combi-
nation of the terms “therapeutic” and “diagnostic”) approaches of-
fers an attractive avenue for the concurrent detection and treatment
of cancer. We previously have developed targeted hybrids of adeno-
associated virus and phage particles (AAVP), functional vectors that
enable synchronous ligand-directed and transcriptional delivery of
transgenes (9). In the decade since their introduction, we have val-
idated the delivery of therapeutic genes via peptide-directed AAVP
vectors to xenograft and transgenic models of tumors such as soft-
tissue sarcomas (10), glioblastomas (11), pancreatic neuroendocrine
tumors (12), and even to dogs with various native tumors (13).
In the present study, the AAV component of the particle provides
a theranostic agent, the human Herpes simplex virus thymidine kinase
type-1 (HSVtk) gene, for molecular–genetic imaging and/or suicide
gene therapy, and the phage component of the particle incorporates
the targeting moiety, a short ligand peptide motif expressed as an in-
frame fusion within the minor capsid protein (pIII) (9). As a proof of
concept for ligand-directed theranostics in IBC, we have chosen
78-kD glucose-regulated protein (GRP78) as a promising tumor
target in human breast cancer (14). Under physiological conditions,
GRP78 is expressed in the endoplasmic reticulum with pleomorphic
functions in protein folding and assembly (15); however, as a stress-
response chaperone in cancer (16), GRP78 relocalizes to the cell
surface (17). Our group originally demonstrated that cell-surface
GRP78 enables tumor targeting by circulating ligands in vivo (18,
19), an observation confirmed by independent investigators (20, 21).
Both hormone receptor-positive and -negative breast cancers appear
to overexpress GRP78 (22, 23), and high levels of GRP78 in patients
correlate to poor responses to chemotherapy and lower survival rates
(24). However, despite its promise as a functional molecular target
and as a potential prognostic marker in human breast cancer, the
role of GRP78 in patients with IBC remains unclear, hence the
impetus for this work.
Here we investigated the presence of cell-surface GRP78 in the
context of human IBC, explored the theranostic value of ligand
peptide-directed AAVPs or motif loop-grafted monoclonal antibody
fragments, and compared the potency of the cognate human GRP78
native stress-inducible promoter (hGRP78) to that of constitutive
CMV promoter-based transcription. In several relevant preclinical
models of IBC, ligand-directed and transcriptional targeting of
GRP78 provided efficient tumor visualization by PET imaging as
well as the selective cellular destruction of orthotopic IBC tumors,
with minimal off-target activity detected. Taken together, these re-
sults represent a meaningful step toward the translation into
clinical practice of an AAVP-based ligand-directed and tran-
scriptional theranostics against IBC and potentially against
other aggressive breast cancers.
Results
GRP78 Is Strongly Expressed in Human IBC. To evaluate the protein
levels of GRP78 in human IBC systematically, we examined
GRP78 expression by immunohistochemistry (IHC) on a dis-
covery set of index IBC patients (n = 5) who underwent surgery
at the University of New Mexico Comprehensive Cancer Center
(UNMCCC). Having observed moderate-to-strong positivity for
GRP78 in this small pilot study (Fig. 1 A–F), we next investigated
protein levels in a relatively larger validation set (n = 20) from
representative IBC patients having surgery at The University of
Texas M. D. Anderson Cancer Center (MDACC), with similar
results (Fig. 1 G–L). Staining of the initial discovery set revealed
moderate-to-strong positivity in two index cases (Fig. 1 A and C)
and moderate positivity in three index cases (Fig. 1E), suggesting
the presence of this protein on the cell surface as demonstrated
by our previous study (19). The validation set from the MDACC
confirmed similar patterns, with moderate-to-strong GRP78
levels (Fig. 1 H and I); intense GRP78 expression was detected in
tumor cells infiltrating white adipose tissue (Fig. 1J) or tumor
stroma (Fig. 1K) as well as in lymph node metastases (Fig. 1L).
Together, results from these independent datasets provide evi-
dence that GRP78 is a candidate molecular target in IBC.
A GRP78-Targeting Peptide Motif Is a Ligand for IBC- and Aggressive
Breast Cancer-Derived Cells. To gain quantitative functional targeting
insight (Fig. 2), we initially characterized the selective binding of the
GRP78-binding peptide motif WIFPWIQL (19) to a representative
panel (n = 9) of immortalized breast epithelial cells and tumorigenic
breast cancer cells in vitro. We assessed the binding of phage par-
ticles displaying WIFPWIQL and control (insertless) phage particles
to tumorigenic cell lines recapitulating different breast cancer sub-
types, including primary invasive ductal (human, BT474), invasive/
metastatic [human, SK-BR-3, MCF7, MDA-MB-231; murine, 4T1.2,
EF43.fgf4 (25)], and IBC [human, MDA-IBC-3, SUM190 (26, 27)]
breast cancer cells and also to a nontumorigenic mammary cell line
(human, MCF10A). Phage binding was evaluated by the BRASIL
(biopanning and rapid analysis of selective interactive ligands)
methodology (28) and revealed a particularly marked interaction of
GRP78-targeting phage particles with the cell surface of human IBC
and murine highly aggressive breast cancer cell lines (Fig. 2A). This
interaction was inhibited significantly (P < 0.05 by two-tailed Stu-
dent’s t test) after incubation with a neutralizing anti-GRP78 anti-
body (Fig. 2B), indicating a specific interaction between the
WIFPWIQL peptide and cell-surface GRP78. Consistent with
this finding, flow cytometry analysis revealed abundant cell surface-
associated GRP78 expression in the human and murine lines, as
shown in Fig. 2C for SUM190 cells, further corroborating the value
of GRP78 as a cell-surface receptor target in human IBC.
Ligand-Directed Imaging of IBC-Bearing Mice. To investigate whether
cell-surface–associated GRP78 targeting could be exploited in li-
gand-directed strategies for in vivo imaging, we next completed
experiments with near-infrared (NIR)-based tracing of fluorescently
labeled phage. Either GRP78-targeting or control phage particles
were conjugated side-by-side to an infrared dye (RDye 800CW) and
subsequently were administered i.v. to orthotopic SUM190 IBC-
bearing mice (n = 5 mice per group). Phage particles were imaged
by whole-body NIR fluorescence (NIRF) and revealed specific lo-
calization of GRP78-targeting particles to established IBC xeno-
grafts (Fig. 3A). As expected, nonspecific phage accumulation was
equally detected in the hepato-splenic organs because of the
documented retention of phage within the reticuloendothelial sys-
tem (29–31) (see SI Discussion for further discussion of the po-
tential for AAVP in the clinical setting), regardless of the peptide
displayed, and served as an additional internal control. Relative
quantification of tumor-associated signals revealed a sixfold higher
intensity of GRP78-targeting phage homing than control phage
homing (Fig. 3B). These data confirm that circulating phage parti-
cles displaying a GRP78-targeting peptide localized specifically to
tumor lesions in a preclinical model of IBC.
To ensure that the ligand motif WIFPWIQL (19) would target
cell-surface GRP78 in vivo outside of the context of phage parti-
cles (in which up to five recombinant peptide motifs are displayed
in pIII), we next loop-grafted the GRP78-targeting peptide into a
human fragment antigen-binding (Fab) backbone to obtain a
convenient standard entity that retains the GRP78-binding at-
tributes, exhibits inherent biological stability, and has a single
antigen-binding site, thus ruling out the possibility that peptide
avidity (rather than affinity) might account for GRP78-targeting
phage homing in vivo. The loop-grafted GRP78-targeting Fab
was initially evaluated by ELISA and showed concentration-
dependent binding to immobilized human recombinant GRP78
relative to a control Fab (Fig. 4A). We next evaluated the in vivo
efficacy of this GRP78-targeting Fab in mouse isogenic EF43.fgf4
mammary tumors (25), enabling us also to evaluate the efficacy
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of the WIFPWIQL motif across different in vivo models. This
model was selected because of its pathological similarity to the
clinical disease, including a high level of inflammation, extensive
angiogenic potential, rapid proliferation, and local invasion in an
animal with an intact immune system. The IRDye 800CW-labeled
GRP78-targeting Fab was administered i.v. (20 μg per mouse) to
mice bearing orthotopic implants of EF43.fgf4 tumor cells, fol-
lowed by evaluation of NIR signals at different time points. Within
the context of this model, the tumor was specifically imaged by
whole-body NIRF with the GRP78-targeting Fab but not with the
control Fab (Fig. 4B). Quantification of signal at the tumor site
showed a significant threefold increase in fluorescence (Fig. 4C)
that persisted up to 72 h (P < 0.05 relative to the control Fab, by
two-tailed Student’s t test). Collectively, these results confirm the
reliability of a single binding unit of the GRP78-targeting peptide
WIFPWIQL in a preclinical IBC model, regardless of the scaffold
displaying the peptide motif.
Cell-Surface GRP78-Targeting Theranostics Based on Ligand-Directed
AAVP Particles. Having characterized the binding attributes of the
WIFPWIQL motif, we next engineered GRP78-targeting AAVP
particles (9, 32) to enable theranostic function in preclinical
models of human IBC in immunodeficient mice and in aggressive
mouse mammary cancers in immunocompetent mice. Briefly, we
inserted into the M13-based phage genetic backbone an AAV
genomic cassette containing the HSVtk transgene under the
control of either the standard constitutive and highly efficient
CMV promoter or the stress-inducible human GRP78 (hGRP78)-
selective promoter (33, 34) to compare the two promoters directly
in vivo. In this system, the HSVtk transgene may function as a
serial noninvasive molecular–genetic imaging sensor and reporter
in the presence of specific radiolabeled substrates (35). We
administered either GRP78-targeting or control AAVP particles to
mice bearing SUM190 orthotopic tumors. Mice received control or
GRP78-targeting AAVP on days 0 and 5, andHSVtk expression was
assessed on days 6 and 16 by whole-body PET imaging immediately
after i.v. administration of the [124I]-2-fluoro-5-iodo-1-β-D-arabino-
furanosyl-uracil ([124I]-FIAU) substrate (Fig. 5A) (34). Compared
with the CMV promoter, the hGRP78 promoter conferred much
higher tumor-detection sensitivity to the GRP78-targeting AAVP,
in terms of signal-to-noise ratio (Fig. 5B, whole-body PET, and Fig.
5C, tumor-associated signal quantification). The low background
signal in the control is caused by the affinity of [124I]-FIAU for
endogenous thymidine kinases, especially in highly proliferative
tumor cells in which TK1 is particularly active. Longitudinal radial
profiles of explanted tumors (Fig. 5D) from IBC-bearing mice re-
ceiving GRP78-targeting (either CMV or hGRP78 promoter) or
control AAVP revealed significant ligand-directed tumor accumu-
lation of both vectors (P < 0.05 by two-way ANOVA followed by
Bonferroni’s test) at day 16 after AAVP administration (Fig. 5E),
when the experiment was terminated. No off-target HSVtk activity
was detected in organs that did not have lesions, including muscle,
kidney, heart and liver (Fig. 5F), thus indicating targeting specificity.
Collectively, these spatiotemporal quantitative data in preclinical
settings establish the value of targeting GRP78 for noninvasive se-
rial molecular–genetic imaging of IBC.
Having demonstrated the diagnostic attributes of targeting cell-
surface GRP78 with AAVP constructs in IBC, we next evaluated
the therapeutic potential of this ligand-directed theranostic plat-
form technology. AAVP-transduced HSVtk also may act as a cell
suicide-inducing gene in the presence of ganciclovir (GCV), which
is converted by the thymidine kinase enzyme to a cytotoxic com-
pound (36). To investigate the efficacy of the GRP78-targeting
AAVP in breast cancer treatment, we used the syngeneic EF43.fgf4
Fig. 1. GRP78 protein levels in specimens derived
from human IBC patients. Archival formalin-fixed
paraffin-embedded (FFPE) tissue slides from IBC pa-
tients were stained with anti-GRP78 antibody, and
signals were revealed with a 3,3′-diaminobenzidine-
tetrahydrochloride (DAB) substrate. (A–F) Discovery
set. Invasive mammary carcinoma in representative
biopsies from patients with clinically diagnosed IBC.
(A, C, and E) H&E staining. (B, D, and F) Immuno-
histochemical staining for GRP78. (Magnification:
40×.) (G–L) Validation set. (G) Negative control (iso-
type antibody). (H and I) Representative primary IBC
samples. (J) Representative IBC within white adipose
tissue (WAT). (K) Representative IBC within stroma (S).
(L) Representative metastasis-positive lymph node.
(Magnification: G, 10×; H–L, 20×.)
Fig. 2. Specificity of GRP78-targeting phage parti-
cles. (A) Phage binding to human breast cancer and
murine mammary tumor cell lines. (B) Binding speci-
ficity of GRP78-targeting phage particles was evaluated
in competition assays in the presence of an anti-GRP78
antibody in representative human IBC (MDA-IBC-3,
SUM190) and murine mammary tumor (4T1.2, EF43.
fgf4) cell lines. Rabbit immunoglobulins served as an
isotype antibody negative control, and BSA served as
a negative protein control. Phage binding is displayed
as mean ± SEM; *P < 0.05 relative to control antibody
incubation, by two-tailed Student’s t test. (C) Repre-
sentative flow cytometry analysis of cell-surface GRP78
expression in human IBC cells (SUM190).
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mammary tumor model (25, 37). Five days after tumor cell
implantation, mice received an i.v. dose of GRP78-targeting
AAVP particles (with either the CMV or the hGRP78 promoter),
control AAVP particles, or vehicle-only (PBS) as negative con-
trols. After 3 d, mice underwent daily GCV treatment for 7 d, and
tumor growth rates were monitored throughout the experiment,
for a total of 15 d. Given the high morbidity and mortality of mice
bearing EF43.fgf4 tumors, we could not extend these therapeutic
experiments for more than 10 d after AAVP administration be-
cause of large tumor burden or lethality in controls. Mice with
size-matched tumors that received GRP78-targeting AAVP par-
ticles (with either the CMV or the hGRP78 promoter) showed
significant tumor reduction compared with the control groups
(Fig. 6A). The evaluation of explanted tumors at the end point
confirmed a significant decrease in tumor growth for animals
treated with either GRP78-targeting AAVP, with a mean re-
duction in tumor volume of 20% for AAVP constructs carrying
the CMV promoter and 46% for AAVP constructs carrying the
hGRP78 promoter (P < 0.01 and 0.001, respectively, relative to the
control AAVP, by two-way ANOVA followed by Bonferroni’s
test) (Fig. 6B). These data show that targeting cell-surface GRP78
with AAVP particles is an efficient strategy for GCV-based suicide
therapy against experimental breast cancer. Overall, the results
reported in Figs. 5 and 6 demonstrate the value of ligand-directed
theranostic AAVP approaches.
Discussion
Here we report a proof-of-concept experiment for a ligand-
directed theranostic-enabling platform that is readily translatable
into clinical applications for diagnosis and therapy of IBC.
The presence of systemically accessible tumor- and/or vascular
endothelial cell-specific surface receptors is expected to favor the
targeted delivery of active imaging agents and/or therapeutic drugs
(38), with consequent improvement in therapeutic indices and with
reduced side effects. The possibility of enhancing drug efficacy by
concentrating an active agent at the tumor site therefore is a
promising alternative for aggressive breast cancer therapy; however,
only a small number of tumor-specific receptors have been identi-
fied so far. Chaperone heat-shock and glucose-regulated proteins
have only recently—and quite unexpectedly—been described as
abundant (protein “moonlighting”) on tumor and neovascular cell
surfaces (16–18). Among these proteins, GRP78 is part of an evo-
lutionarily conserved endoplasmic reticulum-linked stress-response
mechanism that provides survival signals during environmental and
physiologic stress (39). GRP78 is classically involved with the pro-
cessing of unfolded proteins (15); however, recent mechanistic in-
sights also place this protein at the cell surface with the potential to
influence signal transduction (40, 41). GRP78 has been targeted
previously for anticancer treatment (42, 43). Indeed, our group has
reported GRP78 overexpression in a limited set of matched pri-
mary/metastatic tumors from patients with prostate and breast
cancer, supporting the likelihood of systemic targeting of surface
GRP78 in primary and metastatic disease settings (44, 45).
Based on these considerations, we developed a ligand-directed
AAVP (9) for noninvasive serial imaging and suicide gene therapy
of IBC and for other aggressive breast cancer subtypes in which
GRP78 is highly expressed and in which the protein is accessible
because of its translocation to the tumor cell surface. In the treat-
ment of highly invasive tumors, the availability of new theranostic
tools using molecular–genetic imaging is critical for early diagnosis
and for a rapid change in therapy upon the development of re-
sistance. In particular, given that IBC is often misdiagnosed because
of its atypical disease presentation and/or is understaged because of
the early onset of micrometastasis before distant disease can be
documented (4, 5), an effective molecular methodology for early
tumor detection, staging, and serial monitoring of response and
local or distant disease recurrence clearly remains an unmet medical
need. Attesting to its inherent versatility, ligand-directed AAVP-
based delivery of transgenes in preclinical settings has been
demonstrated successfully in xenograft and transgenic models of
soft-tissue sarcomas (10), glioblastomas (11), and neuroendocrine
pancreatic tumors (12), in addition to the original new technology
report in breast and prostate cancer in tumor-bearing mice a decade
ago (9, 19). Notably, one also could speculate that the described
ligand-directed theranostic approach introduced here could also be
used to determine the precise location of a lesion intraoperatively
and/or to integrate the administration of tumor-directed treatments
based on the recent report of an enabling AAVP-based nanotech-
nology platform (46). (See SI Discussion for a further discussion of
the potential for AAVP in the clinical setting.)
In aggressive human cancer subtypes, such as IBC, for which
precision medicine treatments are urgently needed but lacking,
our strategy is attractive for future clinical applications, given the
possibility of coupling noninvasive imaging for serial biopsy-free
disease monitoring to treatment in a single i.v. administration.
We propose the use of the hGRP78 promoter as an effective and
specific transational transcription-directed strategy as demonstrated
Fig. 3. NIR-labeled GRP78-targeting phage particles for preclinical imaging of
human IBC xenografts. (A) Human SUM190 orthotopic IBC-bearing nude mice
(n = 5 per group) received vehicle only, fluorescent control phage, or GRP78-
targeting phage particles. Fluorescence images were obtained 24 h after injection.
Arrows indicate tumor localization (ventral view). (B) Relative quantification of
fluorescence signals at the SUM190 cell-derived tumor xenograft site.
Fig. 4. NIR-labeled GRP78-targeting Fab for preclinical imaging of breast
cancer xenografts. (A) Binding specificity of the Fab loop-engrafted GRP78-
targeting peptide was assessed in vitro by ELISA on immobilized human
recombinant GRP78. BSA served as a negative control protein. (B) EF43.fgf4
orthotopic breast cancer-bearing mice (n = 5 per group) received i.v. IRDye
800CW alone (IR-dye), IRDye 800CW-labeled control Fab, or IRDye 800CW-
labeled loop-grafted GRP78-targeting Fab. Images were obtained serially at
24, 48, and 72 h after administration. Arrows indicate tumor xenograft lo-
calization (ventral view). (C) Relative signal quantification is represented as
the signal-to-noise ratio of the indicated treatments to autofluorescence at
the tumor site after 24, 48, and 72 h. Results are represented as mean ± SEM;
*P < 0.05 relative to control Fab, by two-tailed Student’s t test.
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by the clear molecular–genetic imaging results and a trend in the
therapeutic results presented in this work. The benefits of the
hGRP78 promoter reside not only in its specific activation in
GRP78-expressing tumor cells but also in the persistence of
HSVtk gene expression over the CMV promoter, which may be
subjected to silencing by eukaryotic cells (33, 34). Moreover,
because GRP78 is a stress-induced protein, one could predict
that the harsh tumor microenvironment would increase GRP78
transcription in a positive feedback loop that would potentiate
protein production, cell-surface relocalization, and, ultimately,
the availability and accessibility of this molecular target. Notably,
the advantage of the hGRP78 promoter is expected to be evi-
dent when translated to patients, in whom the effects can be
evaluated over long periods of time (several weeks to months)
rather than in the mere 10-d framework possible in our pre-
clinical therapeutic experiments.
In conclusion, in the present work we designed and introduced
a GRP78-targeting theranostic system and have validated it in
multiple preclinical settings. If translational applications are
successfully developed, the platform can be exploited for highly
specific molecular–genetic imaging and treatment of IBC and
potentially other aggressive human breast cancer subtypes. Gene
therapy has been recognized as a great promise for the treatment
of cancer, but the lack of a robust system to deliver reporter and/
or therapeutic transgene(s) effectively and specifically is a seri-
ous limiting factor. The AAVP-based strategy reported here has
its maximum diagnostic and therapeutic efficacy targeted at the
tumor site, making it a promising candidate for the development
of first in-human clinical trials for tumors such as IBC and ag-
gressive variant prostate cancer (46), which are in the advanced
planning stage. Finally, in the future other tumor-specific ligand-
receptor systems and/or inducible promoters may be integrated
easily into the AAVP-based platform.
Fig. 5. Molecular–genetic imaging based on GRP78-targeting AAVP in a preclinical model of human IBC. (A) Scheme of time points of AAVP administration,
[124I]-FIAU dosing, and PET/CT imaging acquisition. A representative IBCmodel of human SUM190 tumor xenografts in nude mice was used. (B) Maximum intensity
full-body projections of tumor-bearing mice receiving control AAVP with the CMV promoter, GRP78-targeting AAVP with the CMV promoter, or GRP78-targeting
AAVP with the hGRP78 promoter. Representative PET/CT images are shown. Images were acquired at day 6 and day 16 after the first AAVP administration. All PET
images shown are set out to 3% injected dose per gram of tissue (ID/g). Dashed lines indicate the tumor location. (C) Group average tumor xenograft concen-
trations (Left) and standard tumor xenograft uptake (Right) (normalized to baseline, *P < 0.05 by two-way ANOVA followed by Bonferroni’s test). In the box-and-
whiskers plots the horizontal line represents the median, the box represents quartiles, and whiskers represent 5–95% confidence limits. (D) Representative
longitudinal radial profile of AAVP particle distribution within tumor xenografts. (E) Average [124I]-FIAU concentration (tumor profile plot) at day 6 (Upper)
and day 16 (Lower) for tumors treated with control AAVP with the CMV promoter, GRP78-targeting AAVP with the CMV promoter, or GRP78-targeting AAVP
with the hGRP78 promoter. (F) AAVP biodistribution: average [124I]-FIAU concentration in tumor-negative control tissues at day 6 and day 16.
Fig. 6. Therapeutic approach with cell suicide-inducing transgene delivery by
GRP78-targeting AAVP in a preclinical model of highly aggressive breast can-
cer. (A) EF43.fgf4 orthotopic breast cancer-bearing mice (n = 6 per group)
received vehicle only, control AAVP, or GRP78-targeting AAVP with either the
CMV or the hGRP78 promoter to drive the HSVtk gene expression. GCV was
administered daily starting 3 d after AAVP administration. (B) Explanted tumor
volumes at the end of the experiments. Shown are themean tumor volumes at
day 6 of GCV treatment in mice that received vehicle only, control AAVP, or
GRP78-targeting AAVP with either the CMV or the hGRP78 promoter: 508 ±
65, 753 ± 52, and 940 ± 95 mm3, respectively. **P < 0.01, ***P < 0.001 relative
to the control AAVP, by two-way ANOVA followed by Bonferroni’s test.
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Materials and Methods
This study adheres strictly to current medical ethics recommendations and
guidelines on human research and has been reviewed and approved by the
Clinical Ethics Service, Institutional Biohazard Committee, Clinical Research
Committee, and Institutional Review Board at the corresponding institu-
tions. The animal experiments reported in this paper were conducted in full
compliance with MDACC Institutional Animal Care and Utilization Com-
mittee (IACUC) policies and procedures, which follow a strict current guide
care and use of laboratory animals (47). Before the initiation of experiments,
all protocols and procedures involving animals were reviewed and approved
by the IACUC of the site performing the experiment.
Reagents and all experimental procedures, such as the design of targeted
AAVP and all in vivo and in vitro applications, are fully described in SI Ma-
terials and Methods.
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SI Materials and Methods
Cell Lines, Reagents, and Human Specimens.The cell lines MCF10A,
BT474, SK-BR-3, MCF7, and MDA-MB-231 were purchased
from the American Type Culture Collection (ATCC), and the cell
line SUM190 was purchased from Asterand Bioscience. The cell
line MDA-IBC-3 was obtained from The Morgan Welch In-
flammatory Breast Cancer Research Program at the MDACC,
and the 4T1.2 and EF43.fgf4 cell lines were previously reported
(25, 48, 49). MCF10A cells were maintained in MEGM mam-
mary epithelial cell growth medium (Lonza); BT474 cells were
maintained in Hybri-Care medium (ATCC) with 1.5 g/L sodium
bicarbonate; SK-BR-3 cells were maintained in McCoy’s 5a
(Modified) Medium (Lonza); MCF7 and MDA-MB-231 cells
were maintained in DMEM/F12 (Invitrogen Life Technologies);
4T1.2 cells were maintained in RPMI-1640 (Lonza); SUM190
and MDA-IBC-3 cells were maintained in F12 medium with
insulin (1 mg/mL) and hydrocortisone (1 mg/mL) (Lifeline Cell
Technology); EF43.fgf4 cells were maintained in DMEM (In-
vitrogen Life Technologies) with 5 ng/mL mouse EGF and 1 μg/mL
bovine insulin (both from Sigma). All media were supple-
mented with 10% (vol/vol) FBS (Invitrogen Life Technologies),
penicillin, and streptomycin. Human cell line identities were
confirmed by short tandem repeat microsatellite loci analysis.
Frozen stocks of all cell lines were generated at the time of au-
thentication and were thawed no more than 3 mo before ex-
perimental use. All cells were tested and documented to be free
of Mycoplasma species contamination. Human recombinant
GRP78 was commercially obtained from Stressgen Bioreagents.
De-identified archival human IBC samples were from patients of
the UNMCCC (discovery set) or the MDACC (validation set).
This study adheres strictly to current medical ethics recom-
mendations and guidelines on human research, and has been
reviewed and approved by the Clinical Ethics Service, In-
stitutional Biohazard Committee, Clinical Research Committee,
and Institutional Review Board at the corresponding institutions.
IHC. FFPE samples from the University of New Mexico Human
Tissue Repository were stained in a Ventana Discovery XT
Biomarker Platform with standardized apparatus, reagents, and
protocols provided by the manufacturer (Ventana Medical Sys-
tems). Primary anti-GRP78 rabbit monoclonal antibody (Cell
Signaling Technology) was used at 1:200. FFPE samples from the
Pathology Core at the MDACC were stained with 10 μg/mL anti-
GRP78 antibody (Santa Cruz Biotechnology) overnight at 4 °C.
Following incubation in anti-goat HRP-conjugated secondary anti-
body (Santa Cruz Biotechnology), signal was reveled with a DAB
chromogenic substrate (Dako). Staining of patient samples was
evaluated with standard pathology protocols, applying a four-value
intensity score (0, none; 1+, weak; 2+, moderate; 3+, strong).
Surface Detection of Membrane-Associated GRP78 by Flow
Cytometry. After harvesting by Accutase (Sigma) proteolytic di-
gestion, SUM190 cells were incubated with Ham’s F12 medium
supplemented with 30% (vol/vol) FBS and 10 μg/mL purified
human IgG (I2511; Sigma) for 20 min at 4 °C. Cells were
washed with cold PBS, and 106-cell aliquots were incubated
with 1 μg of phycoerythrin (PE)-conjugated mouse antiGRP78
(ab12223; Abcam) or PE-conjugated isotype control for 40 min
at 4 °C in 100 μL of staining buffer (0.5% BSA in PBS). After
two washes, cells were resuspended in ice-cold PBS for flow
cytometry analysis (AccuriC6; BD). Data were analyzed by
FlowJo v. 10.0.8 (FlowJo LLC).
Phage-Binding Assays. Phage particles were amplified in host
bacteria and purified as described (50). Oligonucleotide inserts
were amplified by PCR and sequenced as described (50). The
BRASIL methodology (28) was performed to evaluate, validate,
and quantitate cell–phage binding. A polyclonal rabbit anti-
GRP78 antibody (Santa Cruz Biotechnology) and/or an un-
related isotype control antibody at the same dilution were used
to evaluate competitive inhibition of phage binding as indicated.
Preparation of the Loop-Grafted GRP78-Targeting Fab. The heavy-
chain CDR3 (HCDR3) domain of the original Fab (anti-tetanus
toxoid) cloned into pComb3XTT was replaced with an in-frame
oligonucleotide coding the WIFPWIQL [GRP78-binding (19)]
peptide motif by an overlapping PCR approach. The DNA
fragment encoding the light chain, the constant light chain (CL),
and the variable heavy chain (VH) up to the framework region 3
(FR3) was PCR-amplified with the primers SfiIVL-F (5′-GGGCC-
CAGGCGGCCGAGCTC-3′) and TTFR3-R (5′-TCTCGCAC-
AATAATATATGGCCGTGTC-3′). Replacement of HCDR3
with WIFPWIQL was obtained by PCR amplification with the
primers TTFR3GRP78CH1-1F (5′- GACACGGCCATATAT-
TATTGTGCGAGAGTGGGGGGGTGGATCTTCCCGTG-
GATCCAGCTG GGAGGATACGCTATGGACGTCTGG-
GGC-3′) and 3XTT-R (reverse). (5′-AGAAGCGTAGTCCG-
GAACG-TC-3′). All amplifications were completed under standard
PCR conditions with Taq polymerase (Roche). The two DNA
fragments were assembled by overlap extension PCR with the pri-
mers RSC-F (5′-GAGGAGGAGGAGGAGGAGGCGGGGCC-
CAG-GCGGCCGAGCT-3′) and 3XTT-R.
Finally, the Fab-coding DNA was digested with SfiI, ligated
into the pComb3X phagemid vector, and transformed into Es-
cherichia coli strain Top10F (Invitrogen). The Fab was overex-
pressed in Top10F by isopropyl β-D-1-thiogalactopyranoside
(IPTG) induction, purified by cobalt column (Pierce), and la-
beled with IRDye 800CW following the manufacturer’s instruc-
tions (LI-COR).
Design, Genetic Engineering, and Production of GRP78-Targeting
AAVP Particles. Experimental protocols for the generation of li-
gand AAVP-based vectors have been described extensively (9;
reviewed in refs. 32, 51, 52). Briefly, the CMV promoter cassette
and inverted terminal repeats were obtained from pAAV-MCS
(Stratagene) and cloned into the AAVP vector by using standard
molecular genetic protocols. The hGRP78 promoter was PCR-
amplified from pDRIVE01-GRP78(h) v04 (InvivoGen) with the
primers 5′-CACAACGCGTGTGCGGTTACCAGCGGAAAT-
GCC-3′ and 5′-CACACCTAGGGTGCCAGCCAGTTGGGC-
AGCA-3′. The resulting amplicons were digested with MluI
(New England Biolabs) and AvrII (New England Biolabs) and
religated into the AAVP vector backbone. All vectors were
purified from culture supernatant of transformed host bacteria
(MC1061 E. coli), resuspended in PBS (pH 7.4), and centri-
fuged to remove residual bacterial debris. Supernatants con-
taining AAVP particles were titrated by bacterial infection
(k91Kan E. coli). Serial dilutions were plated onto Luria-Bertani
(LB) agar plates supplemented with tetracycline and kanamycin,
and the number of AAVP transduction units (TU) was determined
by bacterial colony counting.
Animal Models. Six- to eight-week-old female BALB/c (immuno-
competent) and BALB/c nu/nu (nude, immunodeficient) mice
(Charles River Laboratory) were kept on a 12-h light/dark cycle.
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Standard rodent chow and water were available ad libitum.
Orthotopic tumors were produced by inoculation of the second
thoracic mammary fat pad with 1 × 106 SUM190 human IBC cells
(BALB/c nu/nu immunodeficient mice) or 5 × 105 EF43.fgf4
mouse mammary tumor cells (BALB/c immunocompetent mice)
in 50 μL of a 50% (vol/vol) growth factor-deprived Matrigel (BD
Biosciences) solution (1:1 vol/vol in PBS). During all imaging
and surgical procedures, mice were anesthetized [250 mg/kg
tribromoethanol or 2% (vol/vol) isoflurane in oxygen], and their
temperature was maintained at 38 °C with a heat lamp. Tumor
growth was monitored closely and recorded with a caliper, and
tumor volume was calculated as (a×b2)/2 cm3 (a, long diameter;
b, short diameter) as described (25, 53). The animal experiments
reported in this paper were conducted in full compliance with
MDACC Institutional Animal Care and Utilization Committee
(IACUC) policies and procedures, which follow a strict current
guide care and use of laboratory animals (47). Before the initi-
ation of experiments, all protocols and procedures involving
animals were reviewed and approved by the corresponding
IACUC of the site performing the experiment.
In Vivo Tumor Imaging with GRP78-Targeting Phage Particles or Loop-
Grafted GRP78-Targeting Fab. Phage particles or Fabs were labeled
with IRDye 800CW and were column purified according to the
manufacturer’s instructions (LI-COR). Fluorescent phage localiza-
tion was evaluated on cohorts of size-matched orthotopic IBC-
bearing mice injected i.v. with either GRP78-targeting or control
(insertless) phage (2 × 1010 TU per mouse). NIRF images were
acquired using the Pearl Impulse imaging system (LI-COR) at
24 h after administration. Fab-based imaging was performed on
cohorts of size-matched orthotopic tumor-bearing mice injected i.v.
with IRDye 800CW-labeled GRP78-targeting or control Fab (20 μg
per mouse). NIRF images were acquired serially over time with
Pearl Impulse (LI-COR) at the 24, 48, and 72 h time points after
Fab administration. Fluorescence signal quantification was per-
formed using ImageJ software with standard settings.
Preclinical Theranostic Studies in Tumor-Bearing Mice. For the in vivo
molecular–genetic imaging and/or suicide therapy studies, 7 d
after orthotopic implantation of SUM190 cells, BALB/c nu/nu
mice received two i.v. doses (1 × 1011 TU per mouse) of GRP78-
targeting AAVP particles (driven by either the CMV or the hGRP78
promoter) or corresponding control AAVP particles. PET imaging
(inviCRO) for the detection of HSVtk-expressing cells was per-
formed by a single i.v. administration of the radiolabeled nucleoside
analog substrate [124I]-FIAU (35). PET scans were obtained with a
microPET R4 scanner (Siemens) equipped with a computer-con-
trolled positioning bed in a 10.8-cm transaxial and 8-cm axial field
of view with no septa and operating in 3D list mode. PET/CT
imaging was performed with an Inveon micro-PET/CT scanner
(Siemens Preclinical Solution). PET and CT image fusion and image
analysis were performed on a standard software program (ASIPro
version 5.2.4.0; Siemens Preclinical Solution). For signal quantifica-
tion, regions of interest were drawn on digitized images, and mea-
sured values were converted from nanocuries per cubic millimeter to
percent of injected dose per gram of tissue as described (34). To
analyze therapeutic potential, immunocompetent BALB/c mice or-
thotopically implanted with isogenic mouse EF43.fgf4 mammary
tumor cells received a single i.v. dose (1 × 1011 TU per mouse) of
each AAVP 5 d after tumor implantation. Treatment with GCV i.p.
at 80 mg·kg−1·d−1 was initiated 3 d after AAVP administration and
was continued daily for 1 wk, when the experiments were terminated.
Statistics. Data were analyzed by two-way ANOVA, followed by
Bonferroni’s test (multiple comparisons) or two-tailed Student’s
t test (paired comparisons). Data are represented as the mean ±
SEM unless otherwise specified. P values of less than 0.05 were
considered statistically significant. All statistical analyses were
performed with Prism 5 software, version 5.01 (GraphPad
Software).
SI Discussion
The Potential for AAVP in the Clinical Setting: Signal Specificity.
Virtually all imaging techniques have limitations related to
nonspecific uptake of the active agent(s) in organs such as the
hepato-splenic and/or the urinary systems. This uptake might
jeopardize their application, especially when evaluating potential
metastases (commonly to the liver). Our technology provides an
intrinsic containment of these limitations to minimize non-
specific signals, thus improving the signal-to-noise ratio. Spe-
cifically, although both GRP78-targeting and control phage
particles are retained avidly by the liver (Fig. 3A, fluorescence
imaging), no HSVtk reporter gene expression can be observed by
PET/CT (Fig. 5B): Because of the lack of a specific receptor on
their surface, hepatic cells do not actively internalize the AAVP
particles, and therefore the transcriptional activity of the vector
is prevented. A further control level of transgene expression is
provided by the hGRP78 promoter, which allows expression of
the HSVtk transgene preferentially in tumor cells where GRP78
is transcriptionally up-regulated (Fig. 5 B, C, and E). Finally, the
specificity of the GRP78-targeting AAVP particles is corrobo-
rated by the reported therapeutic studies, in which no distress
was observed in mice caused by liver (or other organ) failure.
This finding further demonstrates that the cell suicide inducing
transgene HSVtk is not expressed at functional levels in off-tar-
get sites.
The Potential for AAVP in the Clinical Setting: Repeated Testing and
Treatment. The AAVP vector is immunogenic, a characteristic
that is of potential concern for applying this ligand-directed
theranostic platform in the real-time monitoring of patients in
response to repeated treatments. Repeated therapeutic doses of
AAVP can be administered without generating neutralizing an-
tibodies or causing distress to the patient. We previously evalu-
ated the presence of anti-AAVP antibodies in pre- and
posttreatment sera from single- and serial multidose-treated
dogs. In the single-dose arm, we observed a slight increase (1.8-
to 2.0-fold) in anti-AAVP antibody titers posttreatment com-
pared with pretreatment levels. However, we did not observe any
further increase over time in the serial multidose arm (day 7 vs.
d 28 vs. d 56). Importantly, the presence of anti-AAVP anti-
bodies did not affect the ability of AAVP to reduce tumor bur-
den (13). In the present therapeutic study (Fig. 6), a single
injection of AAVP was deemed sufficient because of the fast
growth rate of EF43.fgf4 tumors (∼12 d to achieve a volume of
1,500 mm3). For imaging studies (Fig. 5), two injections were
performed within a 5-d interval. No adverse reaction to AAVP
was observed in either scenario. In support of our present and
previous data, Peacock et al. (54) and, more recently, Krag et al.
(55) assessed the antibody repertoire against phage particles—
the external component of our hybrid system—in both healthy
adults and patients. They observed no significant immune re-
sponse after serial phage infusions, and no adverse reactions
were reported in individuals receiving bacteriophage injections
in either study.
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